文献速递前列腺癌

血清游离甲基化GSTP1 DNA水平与mCRPC生存及多西他赛疗效:3期试验事后分析

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
PubMed 文献 · Eur Urol · 2018-11-19

该研究基于SYNERGY 3期随机试验中600例mCRPC患者,检测基线和多西他赛两周期后血清游离mGSTP1 DNA。基线可检测者占81%,其中53%两周期后转阴;基线不可检测及治疗后转阴均与更长OS相关,转阴还与更长PSA进展时间相关,且独立于其他预后变量。

要点

  • 基线血清游离mGSTP1不可检测与mCRPC患者更长OS独立相关(HR 0.4)。
  • 多西他赛两周期后mGSTP1转阴与更长OS(HR 0.36)和PSA进展时间(HR 0.44)相关。
  • 血清游离mGSTP1是mCRPC潜在预后生物标志物,尚需验证作为替代终点。

核心结论

  • 血清游离mGSTP1 DNA水平与mCRPC患者多西他赛治疗后的OS和PSA进展时间独立相关。
  • 这是首个在mCRPC中外部验证循环表观遗传生物标志物预后作用的研究。

研究设计与样本

  • 基于SYNERGY 3期多中心随机试验的事后分析,该试验评估在mCRPC一线多西他赛化疗中加入custirsen。
  • 采用敏感甲基化特异性PCR检测600例患者基线和多西他赛两周期后的配对血清样本。

主要发现

  • 基线血清游离mGSTP1可检测者458例(81%)。
  • 基线可检测者中,两周期后243例(53%)mGSTP1转阴。
  • 基线mGSTP1不可检测与更长OS相关(HR 0.4,95%CI 0.29-0.55;p<0.00001)。
  • 两周期后mGSTP1转阴与更长OS相关(HR 0.36,95%CI 0.29-0.46;p<0.00001)和更长PSA进展时间相关(HR 0.44,95%CI 0.35-0.56;p<0.00001)。
  • mGSTP1与临床结局的关联独立于其他已确立的预后变量。

临床怎么用

  • 血清游离mGSTP1或可作为mCRPC患者多西他赛治疗的预后分层工具。
  • 需进一步研究验证其作为临床试验替代终点和临床决策工具的潜力。

局限性

  • 分析缺乏影像学无进展生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glutathione S-transferase 1 (GSTP1) expression is inactivated in >90% of all prostate cancers in association with aberrant DNA methylation. Detection of serum free methylated GSTP1 (mGSTP1) DNA is associated with overall survival (OS) and response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) in test and internal validation cohorts. OBJECTIVE: To assess the relationship between serum free mGSTP1 and treatment outcomes in SYNERGY, a phase 3 multicentre randomised trial testing the addition of custirsen to first-line chemotherapy with docetaxel in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Serum free mGSTP1 DNA was measured by a sensitive methylation-specific polymerase chain reaction assay in paired samples (baseline and after two cycles of docetaxel) from 600 patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Associations between serum free mGSTP1 at baseline, change in mGSTP1 after docetaxel, OS, and time to prostate-specific antigen (PSA) progression were examined using Cox proportional hazards models and Kaplan-Meier methods. RESULTS AND LIMITATIONS: Serum free mGSTP1 was detectable at baseline in 458 (81%) patients. Of those with detectable mGSTP1 at baseline, mGSTP1 became undetectable after two cycles in 243 (53%). Undetectable mGSTP1 at baseline was associated with longer OS (hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.29-0.55; p<0.00001). The event of mGSTP1 becoming undetectable after two cycles of chemotherapy was associated with longer OS (HR 0.36, 95% CI 0.29-0.46; p<0.00001) and longer time to PSA progression (HR 0.44, 95% CI 0.35-0.56; p<0.00001). Associations between mGSTP1 and clinical outcomes were independent of other established prognostic variables. Analysis was limited by the lack of radiographic progression-free survival data. CONCLUSIONS: This is the first study to externally validate the prognostic role of a circulating epigenetic biomarker in mCRPC. Further studies are needed to validate serum free mGSTP1 as a surrogate endpoint for clinical trials and as a potential clinical decision tool. PATIENT SUMMARY: In this study, we confirmed that a blood marker predicted outcomes after chemotherapy for metastatic prostate cancer. This marker may accelerate future clinical trials of new therapies and be useful in the clinic to guide treatment decisions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Mahon KL, Qu W, Lin HM, et al. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. Eur Urol. 2018. PMID: 30466891. doi:10.1016/j.eururo.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。